Case Summary: 

We are pleased to share the success story of dual approvals in the EB-2 NIW and EB1A categories. These approvals were granted to a Scientist III, Research & Development from India. At the time of filing, the client was employed in the United States and had already established a strong reputation for advancing drug repurposing, nanoparticle-based delivery systems, and treatment strategies for critical diseases such as cancer and COVID-19. Her research continues to shape the direction of modern drug development and therapeutic innovation.

Advancing Pharmaceutical Innovation for Public Health

The client’s work focuses on designing smarter ways to repurpose existing drugs and create novel delivery systems that improve therapeutic outcomes. By leveraging nanotechnology, she has developed approaches that allow medications to be delivered more efficiently and with greater precision, making them more effective in combating complex diseases. Her studies on drug repurposing for oncology and infectious diseases have provided a faster, more cost-effective pathway for translating laboratory discoveries into viable treatments for patients.

Global Recognition Through Publications and Citations

Her scholarly output includes 26 peer-reviewed journal articles, 16 conference abstracts, and 4 book chapters, many of which appear in highly selective journals in the pharmaceutical sciences. With more than 1,100 citations, her work has been referenced by independent researchers across multiple continents, demonstrating its broad relevance and international impact. 17 of her publications rank among the most highly cited in pharmacology and toxicology for their publication years, underscoring the significance of her contributions.

Peer Recognition and Expert Validation

In addition to her authorship record, the client has completed over 70 peer reviews for top journals, a responsibility reserved for leading experts whose insights are trusted to uphold the integrity of scientific publishing. Independent recommenders, many of whom have never collaborated with her directly, affirmed the originality and significance of her work, emphasizing that her contributions are actively shaping ongoing research in cancer therapeutics and drug delivery science.

One recommender stated:

“[Client] is an invaluable asset to our field for her dedication to the scalable development of nanoparticles to ensure a superior therapeutic delivery of drugs, and I believe her work is essential to continued progress in pharmaceutical development and target drug delivery for disease treatment.”

This testimony, along with other expert opinions, reinforced the case by demonstrating that her influence is both independent and international, further confirming her position at the forefront of pharmaceutical innovation.

Strengthening U.S. National Interest

The petitions demonstrated that the client satisfied multiple regulatory criteria, including authorship in leading journals, judging the work of peers, and original contributions of major significance. By continuing her work in the United States, she will advance drug development strategies that align with critical national health priorities, reducing both the cost and time required to deliver effective therapies to patients.

At NAILG, we are honored to celebrate this dual success, which highlights how world-class expertise in pharmaceutical sciences strengthens not only the research community but also the broader public health landscape. These approvals reflect both her past accomplishments and the promise of her continued contributions to the United States.